Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

Fiche publication


Date publication

février 2020

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Pr BOUCHE Olivier, Pr GHIRINGHELLI François, Pr LEPAGE Côme, Dr KAMINSKY Marie-Christine


Tous les auteurs :
Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F,

Résumé

Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying patients who may have a chemotherapy-free interval (CFI) after IC are two major challenges.

Référence

Br. J. Cancer. 2020 Feb 4;: